Genomes and Genes
Summary: Compounds which inhibit or antagonize the biosynthesis or actions of aldosterone.
Publications233 found, 100 shown here
- Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionBertram Pitt
University of Michigan, Ann Arbor, USA
N Engl J Med 348:1309-21. 2003....
- Review of aldosterone- and angiotensin II-induced target organ damage and preventionAllan D Struthers
Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Tayside DD1 9SY, Dundee, UK
Cardiovasc Res 61:663-70. 2004....
- Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activityJane A Leopold
Whitaker Cardiovascular Institute, 700 Albany Street, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Nat Med 13:189-97. 2007..These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity...
- Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysisPuneeta Tandon
Hospital Clinic, Liver Unit, Barcelona, Spain
J Hepatol 53:273-82. 2010Renin-angiotensin-aldosterone antagonists [ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), aldosterone antagonists (AA)] are potential therapies for portal hypertension...
- Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiolIngrid J M Duijkers
Dinox, Groningen, The Netherlands
Eur J Contracept Reprod Health Care 15:314-25. 2010..To compare the effects on ovarian activity of two oral contraceptives containing nomegestrol acetate (NOMAC)/17 beta-oestradiol (E2) or drospirenone (DRSP)/ethinylestradiol (EE)...
- Eplerenone in patients with systolic heart failure and mild symptomsFaiez Zannad
INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
N Engl J Med 364:11-21. 2011..We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms...
- Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarctionCarmem Luíza Sartório
Medizinische Klinik und Poliklinik I, Universitatsklinikum Wurzburg, Bayerische Julius Maximilians Universität Würzburg, Germany
Hypertension 50:919-25. 2007..Underlying mechanisms involve inhibition of vascular angiotensin-converting enzyme upregulation and improvement of endothelial NO synthase-derived NO bioavailability...
- Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesionMassimiliano Caprio
Department of Medicine Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
Circ Res 102:1359-67. 2008In clinical trials, aldosterone antagonists decrease cardiovascular mortality and ischemia by unknown mechanisms...
- Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1Shigeru Shibata
Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
Hypertension 49:355-64. 2007..Aldosterone can directly modulate podocyte function, possibly through the induction of oxidative stress and Sgk1...
- Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivoN J Brown
Departments of Medicine and Pharmacology, Pathology, and Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Kidney Int 58:1219-27. 2000....
- Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patientsCarmine Savoia
Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Hypertension 51:432-9. 2008....
- The evolution of aldosterone antagonistsSusan M Garthwaite
Pfizer Incorporated, Global Project Management, Skokie, IL, USA
Mol Cell Endocrinol 217:27-31. 2004..its release, what is its role in the pathophysiology of cardiovascular disease, how to make and study aldosterone antagonists, and for what medical purposes these agents are useful...
- Use of aldosterone antagonists in heart failureNancy M Albert
Nursing Institute and Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio, USA
JAMA 302:1658-65. 2009b>Aldosterone antagonists are recommended for patients with moderate to severe heart failure (HF) and systolic dysfunction...
- Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosisMorag Young
Endocrine Genetics, Prince Henry s Institute of Medical Research, Clayton, Victoria 3168, Australia
Endocrinology 144:3848-51. 2003....
- Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelinesBiykem Bozkurt
Winters Center for Heart Failure Research, VA Medical Center, Baylor College of Medicine, Houston, Texas, USA
J Am Coll Cardiol 41:211-4. 2003..This study was designed to investigate the appropriateness and complications of the use of spironolactone for heart failure (HF) in clinical practice...
- Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trialsJustin A Ezekowitz
Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada
Eur Heart J 30:469-77. 2009..Aldosterone blockade has been used to treat acute myocardial infarction (MI) and chronic heart failure...
- Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guidelineJohn W Funder
Prince Henry s Institute of Medical Research, Clayton, Vic, Australia
J Clin Endocrinol Metab 93:3266-81. 2008..Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism...
- Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunctionJames E Udelson
Tufts Medical Center, 750 Washington Street, Boston, MA 02111, USA
Circ Heart Fail 3:347-53. 2010..Few data are available on effects of aldosterone antagonism in patients with mild-to-moderate HF...
- Long-term renal outcomes in patients with primary aldosteronismLeonardo A Sechi
Hypertension Unit, Division of Internal Medicine, Department of Experimental and Clinical Pathology and Medicine, University of Udine, Udine, Italy
JAMA 295:2638-45. 2006..Experimental animal studies indicate that exposure to increased aldosterone levels might result in renal damage, but the clinical evidence supporting this role of aldosterone is preliminary...
- Low-dose spironolactone in the management of resistant hypertension: a surveillance studyDeirdre A Lane
University Department of Medicine, City Hospital, Birmingham, UK
J Hypertens 25:891-4. 2007..This drug was recommended in 133 patients who were already receiving an angiotensin-blocking drug in addition to other therapies...
- Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II Anastasia Chrysostomou
Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria 3052, Australia
Clin J Am Soc Nephrol 1:256-62. 2006..Results suggest no advantage of triple blockade over dual blockade of the renin-angiotensin-aldosterone system to reduce proteinuria...
- Aldosterone antagonist improves diastolic function in essential hypertensionAnna M Grandi
Department of Clinical and Biological Sciences, University of Insubria, Varese, Italy
Hypertension 40:647-52. 2002..This improvement, not accounted for by changes in blood pressure and left ventricular mass, can be therefore ascribed to a direct action of the drug on the myocardium...
- Induction of cardiac fibrosis by aldosteroneP Lijnen
Department of Molecular and Cardiovascular Research, Faculty of Medicine, University of Leuven, Belgium
J Mol Cell Cardiol 32:865-79. 2000....
- Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognitionChristian Otte
Department of Psychiatry and Psychotherapy, University Hospital Hamburg Eppendorf, Hamburg, Germany
Neuropsychopharmacology 32:232-8. 2007..The domains of cognitive function that are impaired after blockade of MR in men, that is, selective attention, visuospatial memory, and mental flexibility/set shifting appear to be remarkably similar to those described in animal studies...
- Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal diseaseAtsuhisa Sato
Department of Internal Medicine, Mito Red Cross Hospital, Ibaraki, Japan
Am J Hypertens 18:44-9. 2005..Additional, larger, prospective, randomized double-blind studies will be needed for general acceptance of this strategy...
- Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose dietTsutomu Wada
Department of Clinical Pharmacology, University of Toyama, Toyama 930 0194, Japan
Endocrinology 151:2040-9. 2010..These results indicate that inhibition of mineralocorticoid receptor might be a beneficial therapeutic approach for diet-induced phenotypes of metabolic syndrome and fatty liver...
- Aldosterone antagonists in congestive heart failureJudith Soberman
Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Dobbs Research Institute, Memphis 38163, USA
Curr Opin Investig Drugs 3:1024-8. 2002..system (RAAS) in the progression of CHF, and increased interest in the use of aldosterone antagonists. While ACE inhibitors have had the largest impact on adverse events in CHF, numerous studies have shown ..
- Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot studyHideo Izawa
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya 466 8550, Japan
Circulation 112:2940-5. 2005....
- Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetesMurray Epstein
University of Miami School of Medicine, Miami, Florida, USA
Clin J Am Soc Nephrol 1:940-51. 2006..Co-administration of EPL50 or EPL100 with an ACE inhibitor as compared with an ACE inhibitor alone significantly reduces albuminuria in patients with diabetes without producing significant increases in hyperkalemia...
- Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patientsR J MacFadyen
Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, UK
Cardiovasc Res 35:30-4. 1997..Experimental data suggest that aldosterone has harmful effects promoting myocardial fibrosis and disturbing autonomic balance. There has been no evidence of these potential effects in intact man...
- Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertensionJames R Sowers
University of Missouri, Columbia, Missouri, USA
Ann Intern Med 150:776-83. 2009....
- Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstructionHoward Trachtman
Department of Pediatrics, Schneider Children s Hospital, New Hyde Park, New York 11040, USA
J Urol 172:1590-4. 2004..We conducted experiments to determine whether administration of spironolactone, a mineralocorticoid receptor antagonist, reduced renal fibrosis in an experimental model of obstructive uropathy...
- Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines CommitteeJaved Butler
Department of Medicine, Division of Cardiology, Emory University, Atlanta, GA, USA
J Card Fail 18:265-81. 2012b>Aldosterone antagonists (or mineralocorticoid receptor antagonists [MRAs]) are guideline-recommended therapy for patients with moderate to severe heart failure (HF) symptoms and reduced left ventricular ejection fraction (LVEF), and in ..
- Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in ratsGenro Fujisawa
Divisions of Endocrinology and Metabolism and Nephrology, Department of Internal Medicine, Jichi Medical School, Minamikawachi, Tochigi, Japan
Transl Res 148:149-56. 2006..The aldosterone produced in the injured liver contributes to the PS-induced hepatic fibrosis...
- Aldosterone target organ protection by eplerenoneAmy E Rudolph
Pharmacia Corporation, Cardiovascular and Metabolic Diseases, 800 N Lindbergh Blvd, T1G T108W, St Louis, MO 63167, USA
Mol Cell Endocrinol 217:229-38. 2004....
- Beneficial impact of spironolactone in diabetic nephropathyKatrine Jordan Schjoedt
Steno Diabetes Center, Gentofte, Denmark
Kidney Int 68:2829-36. 2005..We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on albuminuria and blood pressure in diabetic nephropathy...
- Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive ratsBing S Huang
University of Ottawa Heart Institute, Ottawa, ON, Canada K1Y 4W7
Am J Physiol Regul Integr Comp Physiol 296:R994-R1000. 2009..These results suggest that, in Dahl S rats, high salt intake increases aldosterone synthesis in the hypothalamus and aldosterone acts as the main MR agonist activating central pathways contributing to salt-induced hypertension...
- Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final resultsAlessandro Boccanelli
Department of Cardiovascular Diseases, San Giovanni Addolorata Hospital, Roma, Italy
Eur J Heart Fail 11:68-76. 2009..Aldosterone receptor antagonists improve outcome in severe HF, but no information is available in NYHA class II...
- Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control studyJürgen Dinger
Director, ZEG Berlin Center for Epidemiology and Health Research, Invalidenstrasse 115, 10115 Berlin, Germany
J Fam Plann Reprod Health Care 36:123-9. 2010..The secondary objective was to investigate the VTE risk associated with drospirenone/ethinylestradiol (DRSP/EE) in comparison to low-dose LNG/EE...
- Long-term effect of spironolactone on cardiac structure as assessed by analysis of ultrasonic radio-frequency signals in patients with ventricular hypertrophyNagahiro Nishikawa
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita 565 0871, Japan
Circ J 69:1394-400. 2005....
- Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)Faiez Zannad
INSERM, Centre d Investigation Cliniques CIC 9501 and U961, CHU and Department of Cardiology, Nancy University, Nancy, France
Eur J Heart Fail 12:617-22. 2010In chronic heart failure (HF), aldosterone antagonists have been shown to improve survival in patients with low ejection fraction and moderate-to-severe symptoms [New York Heart Association (NYHA) classes III and IV]...
- Spironolactone improves diastolic function in the elderlyChanwit Roongsritong
Division of Cardiology, Texas Tech University Health Sciences Center, Lubbock, TX 79430 9410, USA
Clin Cardiol 28:484-7. 2005..Increased myocardial fibrosis, a major determinant of diastolic function, has been observed with advancing age. Spironolactone prevents age-related increases in myocardial fibrosis in old normotensive rats...
- Safety of spironolactone use in ambulatory heart failure patientsRicardo J Lopes
Department of Cardiology, Hospital São João 4200 319 Porto, Portugal
Clin Cardiol 31:509-13. 2008..There is limited information on the use, side effects, and withdrawal rate of spironolactone in routine clinical practice...
- Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney diseaseRichard A Preston
Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
Hypertension 53:754-60. 2009....
- Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failureLarisa H Cavallari
Department of Pharmacy Practice, University of Illinois at Chicago, 60612 7230, USA
Pharmacotherapy 30:1-9. 2010..To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure...
- Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathologyJennifer L Wilkinson-Berka
Department of Immunology, Monash University, Commercial Rd, Prahran, Victoria, Australia, 3004
Circ Res 104:124-33. 2009..We make the first report that MR and aldosterone influence retinal vasculopathy, which may involve inflammatory and G6PD mechanisms. MR antagonism may be relevant when developing treatments for retinopathies that target the RAAS...
- Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathyUzma F Mehdi
University of Texas Southwestern Medical Center, 5939 Harry Hines Boulevard, Dallas, TX 75930, USA
J Am Soc Nephrol 20:2641-50. 2009..These results support the need to conduct a long-term, large-scale, renal failure outcomes trial...
- A comparison of the aldosterone-blocking agents eplerenone and spironolactoneAllan Struthers
Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK
Clin Cardiol 31:153-8. 2008..Choice of a specific agent should be based on individual patient issues, such as the nature of heart failure and patient concerns about adverse events...
- Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactonePaul Mulder
Faculte de Medecine et Pharmacie, INSERM U644, 22 Boulevard Gambetta, 76183 Rouen Cedex, France
Eur Heart J 29:2171-9. 2008..Inhibition of aldosterone synthase, the key enzyme in aldosterone formation, could be an alternative strategy for mineralocorticoid-receptor antagonists in congestive heart failure (CHF), but its effect in CHF is unknown...
- Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot studyStefano Bianchi
Unità Operativa Nefrologica, Spedali Riuniti di Livorno, Livorno, Italy
Am J Kidney Dis 46:45-51. 2005..Hence, administration of aldosterone receptor antagonists may provide additional renal benefits to the ACE inhibitors and ARBs...
- Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysisSankar D Navaneethan
Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio 44195, USA
Clin J Am Soc Nephrol 4:542-51. 2009Addition of aldosterone antagonists (AA) might provide renal benefits to proteinuric chronic kidney disease (CKD) patients over and above the inhibition of renin-angiotensin system blockers (RAS)...
- The new biology of aldosteroneJohn M C Connell
MRC Blood Pressure Group, Division of Cardiovascular and Medical Sciences, University of Glasgow, Gardiner Institute, Western Infirmary, Glasgow G11 6NT, UK
J Endocrinol 186:1-20. 2005..These new findings highlight the role of aldosterone as a key cardiovascular hormone and extend our understanding of its role in determining adverse cardiovascular outcomes...
- Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy studyBertram Pitt
University of Michigan Health System, Ann Arbor, Mich, USA
Circulation 108:1831-8. 2003..This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension...
- Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR modelXiaoyan Zhou
Hypertension Research Laboratories, Ochsner Clinic Foundation, New Orleans, LA, USA
Am J Nephrol 24:242-9. 2004....
- The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observationJürgen C Dinger
Center for Epidemiology and Health Research ZEG, 10115 Berlin, Germany
Contraception 75:344-54. 2007..The study was conducted to compare risks of adverse cardiovascular and other events associated with the use of drospirenone (DRSP)-containing oral contraceptives (OCs) and other OCs...
- Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blockerMiki Nagase
Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Hypertension 47:1084-93. 2006....
- Spironolactone improves lung diffusion in chronic heart failurePiergiuseppe Agostoni
Centro Cardiologico Monzino, IRCCS, Istituto di Cardiologia, Universita di Milano, Via Parea 4, 20138 Milan, Italy
Eur Heart J 26:159-64. 2005..Spironolactone improves clinical conditions and prognosis in chronic HF and reduces connective tissue matrix turnover; DLCO abnormalities in chronic HF are related to increase in fibrosis and connective tissue derangement...
- Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation StudyDavid N Juurlink
Department of Medicine University of Toronto, Toronto
N Engl J Med 351:543-51. 2004..Use of angiotensin-converting-enzyme (ACE) inhibitors is also indicated in these patients. However, life-threatening hyperkalemia can occur when these drugs are used together...
- Effects of eplerenone versus losartan in patients with low-renin hypertensionMyron H Weinberger
Hypertension Research Center, Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
Am Heart J 150:426-33. 2005..Agents that block aldosterone at its receptor sites, therefore, should have significant clinical benefit in patients with low-renin hypertension...
- Mineralocorticoid receptor antagonism in experimental atherosclerosisSanjay Rajagopalan
Department of Internal Medicine, University of Michigan, Ann Arbor, Mich, USA srajagop umich edu
Circulation 105:2212-6. 2002..We hypothesized that there is local expression of the mineralocorticoid receptor (MR) in the vasculature and that the use of a selective aldosterone receptor antagonist (SARA) improves endothelial function in early atherosclerosis...
- Aldosterone-induced inflammation in the rat heart : role of oxidative stressYao Sun
Department of Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis 38163, USA
Am J Pathol 161:1773-81. 2002..Spionolactone, PDTC, and NAC each attenuated these responses suggesting ALDO/salt induction of oxidative/nitrosative stress is responsible for the appearance of this proinflammatory phenotype...
- Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high saltWilliam B Lea
Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Kidney Int 75:936-44. 2009..Our study shows that mineralocorticoid receptor antagonism and aldosterone synthase inhibition similarly decrease hypertrophy and interstitial fibrosis of the kidney and heart caused by angiotensin II and high salt...
- Eplerenone: a selective aldosterone receptor antagonist (SARA)J A Delyani
Pharmacia, 4901 Searle Parkway, Skokie, IL 60077, USA
Cardiovasc Drug Rev 19:185-200. 2001..These studies will extend our understanding of selective aldosterone receptor antagonism in the treatment of chronic cardiovascular disease...
- Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in ratsJun Du
Department of Pharmacology, Kagawa University Medical School, Kagawa, Japan
Am J Physiol Renal Physiol 297:F802-8. 2009..The combination of eplerenone and amlodipine improved renal injury more effectively than either monotherapy in high salt-fed DS rats, presumably by achieving their own renoprotective effects...
- Spironolactone use and renal toxicity: population based longitudinal analysisLi Wei
Medicines Monitoring Unit MEMO, Division of Medical Sciences, Ninewells Hospital and Medical School, Dundee DD1 9SY
BMJ 340:c1768. 2010..To determine the safety of spironolactone prescribing in the setting of the UK National Health Service...
- Potassium homeostasis and renin-angiotensin-aldosterone system inhibitorsMatthew R Weir
Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, 22 South Greene Street, Room N3W143, Baltimore, MD 21201, USA
Clin J Am Soc Nephrol 5:531-48. 2010..Moreover, these patients are likely to derive benefit from RAAS inhibition. Rather than denying them an effective treatment, electrolyte levels should be closely monitored in these patients...
- Spironolactone prevents early renal injury in streptozotocin-induced diabetic ratsGenro Fujisawa
Divisions of Endocrinology, Department of Internal Medicine, Jichi Medical School, Minamikawachi, Tochigi, Japan
Kidney Int 66:1493-502. 2004..The present study investigated whether and how mineralocorticoid receptor antagonist spironolactone ameliorates early renal injury in streptozotocin-induced diabetic rats...
- Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implicationsM Epstein
Department of Medicine, University of Miami School of Medicine, Miami, FL, USA
Am J Kidney Dis 37:677-88. 2001..This is a US government work. There are no restrictions on its use...
- Cardiac aldosterone production in genetically hypertensive ratsY Takeda
Second Department of Internal Medicine, Department of Health Sciences, School of Medicine, Kanazawa University, Kanazawa, Japan
Hypertension 36:495-500. 2000..These results suggest that the rat heart produces aldosterone and that endogenous cardiac aldosterone may affect cardiac function and hypertrophy in hypertension in rats...
- Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicityIris Feria
Molecular Physiology Unit, Instituto de Investigaciones Biomedicas, UNAM, Mexico City, Mexico
Kidney Int 63:43-52. 2003....
- Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)Bertram Pitt
University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109, USA
Circulation 118:1643-50. 2008..This subanalysis examined the relationship between eplerenone, serum potassium (K(+)), and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)...
- Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory responseDaniela Fraccarollo
Medizinische Klinik und Poliklinik I, Julius Maximilians Universitat Wurzburg, Wurzburg, Germany
Hypertension 51:905-14. 2008....
- Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blockerYoshiyuki Furumatsu
Department of Kidney Disease and Hypertension, Osaka General Medical Center, Japan
Hypertens Res 31:59-67. 2008..In conclusion, triple blockade of the RAAS was effective for the treatment of proteinuria in patients with non-diabetic nephropathy whose increased urinary protein had not responded sufficiently to a dual blockade...
- Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationshipF Zannad
Centre d'Investigation Clinique INSERM-CHU, Centre Hospitalier Universitaire, Equipe d'Accueil EA 2403, , Nancy, France
Hypertension 38:1227-32. 2001....
- Effect of spironolactone on blood pressure in subjects with resistant hypertensionNeil Chapman
International Centre for Circulatory Health, Imperial College London, 59 North Wharf Rd, London W2 1PG, United Kingdom
Hypertension 49:839-45. 2007..Although nonrandomized and not placebo controlled, these data support the use of spironolactone in uncontrolled hypertension...
- Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculationShuji Arima
Department of Vascular and Geriatric Medicine, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama 589 8511, Japan
J Steroid Biochem Mol Biol 102:170-4. 2006..Thus, in addition to genomic actions, such non-genomic vasoconstrictor actions in the renal microcirculation may contribute to the deleterious renal effects of aldosterone in renal diseases...
- Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndromeRobert W Schrier
Department of Medicine, University of Colorado Denver, Division of Renal Diseases and Hypertension, Aurora, CO 80045, USA
Clin J Am Soc Nephrol 5:1132-40. 2010..The effect of aldosterone in metabolic syndrome is also discussed in this review...
- Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trialLeszek Tylicki
Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
Am J Kidney Dis 52:486-93. 2008....
- Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytesE Harada
Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Japan
Circulation 104:137-9. 2001..Thus, spironolactone may suppress the progression of heart failure by blocking the effects of aldosterone and angiotensin II...
- Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonismRosana Poggio
Heart Failure and Heart Transplant Program, Department of Cardiology, FLENI, Buenos Aires, Argentina
Postgrad Med J 86:136-42. 2010..of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists. High potassium concentrations in heart failure could lead to life threatening events, and therefore ..
- Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damageAnette Fiebeler
Medical Faculty of the Charite, HELIOS Klinikum Berlin, Franz Volhard Clinic, Berlin, Germany
Circulation 111:3087-94. 2005..We tested the hypothesis that reducing aldosterone by inhibiting CYP11B2 or by adrenalectomy (ADX) may ameliorate organ damage. Furthermore, we investigated how much local cardiac aldosterone originates from the adrenal gland...
- Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailabilityToshio Imanishi
Department of Cardiovascular Medicine, Wakayama Medical University, 811 1, Kimiidera, Wakayama City, Wakayama 641 8510, Japan
Hypertension 51:734-41. 2008..Combined treatment with a selective aldosterone antagonist and an angiotensin-converting enzyme inhibitor has additive protective effects on endothelial function and on atherosclerotic changes via decreased nitrosative stress...
- Eplerenone: cardiovascular protectionNancy J Brown
Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
Circulation 107:2512-8. 2003..This review provides an overview of the pharmacology, efficacy, and safety of a new, more selective aldosterone receptor antagonist, eplerenone, in the context of emerging concepts of the role of aldosterone in cardiovascular toxicity...
- Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronismAsterios Karagiannis
Aristotle University of Thessaloniki, Second Propedeutic Department of Internal Medicine, Medical School, Hippokration Hospital, Thessaloniki, Greece
Expert Opin Pharmacother 9:509-15. 2008..It was concluded that eplerenone was as effective as spironolactone in reducing BP in patients with IHA. The risk of mild hyperkalaemia was similar with both drugs...
- High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarctionFarzin Beygui
Cardiology Department and INSERM U 856, Pitie Salpetriere University Hospital, Paris, France
Circulation 114:2604-10. 2006..Whether aldosterone level at presentation for STEMI is associated with adverse outcome remains unknown...
- A review of the medical treatment of primary aldosteronismP O Lim
Department of Cardiology, Wales Heart Research Institute, University of Wales College of Medicine, Cardiff
J Hypertens 19:353-61. 2001..There is thus a timely need to review the literature for effective drug therapies and to speculate on other therapeutic options by taking into account recent advances in understanding of the PA disease pathophysiological process...
- How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?Morten Svensson
Frederiksberg University Hospital, Department of Cardiology and Endocrinology Frederiksberg Copenhagen, Denmark
J Card Fail 10:297-303. 2004....
- Aldosterone antagonists in the treatment of heart failureTodd R Marcy
University of Oklahoma College of Pharmacy, Oklahoma City, OK 73190, USA
Am J Health Syst Pharm 63:49-58. 2006The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart failure are reviewed.
- Spironolactone improves angiotensin-induced vascular changes and oxidative stressAgostino Virdis
Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada
Hypertension 40:504-10. 2002..Our findings suggest that aldosterone may mediate some of angiotensin II-induced vascular effects in hypertension, in part via increased oxidative stress...
- Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertensionMyron H Weinberger
Indiana University School of Medicine, Hypertension Research Center, Indianapolis 46202 5111, USA
Am J Hypertens 15:709-16. 2002..Eplerenone, a selective aldosterone blocker (SAB) that is highly specific for the aldosterone receptor, has the potential to be efficacious in the treatment of hypertension...
- Pharmacology of different progestogens: the special case of drospirenoneR Sitruk-Ware
Rockefeller University and Population Council, New York, NY 10021, USA
Climacteric 8:4-12. 2005..Drospirenone is also available in combination with estradiol as an HRT preparation (1 mg 17beta-estradiol/2 mg drospirenone; Angeliq, Schering AG)...
- Rationale for the use of aldosterone antagonists in congestive heart failureRicardo Rocha
Division of Cardiovascular and Metabolic Diseases, Pharmacia Corp, Skokie, Illinois, USA
Drugs 62:723-31. 2002..These findings suggest the dissociation between cardiovascular lesions and high blood pressure, and highlight the importance of aldosterone in the pathological changes...
- Mineralocorticoid receptor antagonists and endothelial functionBradley A Maron
Harvard Medical School, Brigham and Women s Hospital, Department of Medicine, Cardiovascular Division, 77 Avenue Louis Pasteur, NRB 0630K, Boston, MA 02115, USA
Curr Opin Investig Drugs 9:963-9. 2008..Therefore, the development of newer agents with more favorable side-effect profiles is needed...
- Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001Frederick A Masoudi
Division of Cardiology, Department of Medicine, Denver Health Medical Center, Denver, CO 80204, USA
Circulation 112:39-47. 2005..We studied the adoption of spironolactone therapy after publication of the Randomized Aldactone Evaluation Study (RALES) in national cohorts of older patients hospitalized for heart failure...
- Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptomsO Ylikorkala
Climacteric 8:1-3. 2005
- Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertensionWilliam B White
Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
Circulation 112:1979-84. 2005..In prior studies with DRSP in postmenopausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reductions in blood pressure (BP)...
- Drospirenone and its antialdosterone propertiesA R Genazzani
Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
Climacteric 10:11-8. 2007..The combined actions of drospirenone on sodium and water retention and cardiovascular parameters make it a more attractive therapeutic option as a component of hormone replacement therapy than other synthetic progestins...
- Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular diseaseRichard N Re
Research Division, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
Nat Clin Pract Cardiovasc Med 1:42-7. 2004....
- Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter studyB S Lee
Department of Obstetrics and Gynecology, College of Medicine, Yonsei University, Seoul, Republic of Korea
Maturitas 57:361-9. 2007....
- Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trialDavid F Archer
CONRAD Clinical Research Center, 601 Colley Avenue, Norfolk, VA 23507, USA
Menopause 12:716-27. 2005....
- Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinasShigefumi Nakano
Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Shimotsuga gun, Tochigi 321 0293, Japan
Hypertens Res 28:925-36. 2005..Spironolactone may be useful as a cardioprotective agent to prevent cardiovascular remodeling via the ACE/EGFR/ERK, NAD(P)H oxidase/LOX-1, and Rho-kinase pathways...
- Aldosterone, Autophagy, and Arterial StiffnessJane A Leopold; Fiscal Year: 2013..arterial stiffness by activating autophagy leading to VSMC phenotype transition and suggest further that aldosterone antagonists, interventions to increase G6PD activity, or autophagy modulators may have therapeutic benefit in ..
- Mineralocorticoid Antagonism and Endothelial DysfunctionBERENICE YOLANDE GITOMER; Fiscal Year: 2013..Of note, aldosterone antagonists have been shown to improve endothelial dysfunction in a number of studies in other patient populations...
- Impact of Comorbidity Dyads on Heart Failure Treatment in Older PersonsJerry H Gurwitz; Fiscal Year: 2013..3) to assess the clinical effectiveness and safety associated with the use of ACE inhibitors/angiotensin II receptor blockers (ARBs) and aldosterone antagonists for patients in the HF-chronic kidney disease dyad group.
- Genetic determinants of aldosterone escape in heart failureLarisa Cavallari; Fiscal Year: 2009..goal of this line of investigation is to determine whether genotype is predictive of response to aldosterone antagonists in heart failure...
- ACTION - A CHF Trial Investigating Outcomes of ExerciseGregg Fonarow; Fiscal Year: 2006..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
- HEART FAILURE & NORMAL SYSTOLIC FUNCTION IN OLDER ADULTSFrederick Masoudi; Fiscal Year: 2004..abstract_text> ..
- Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory MonitoringMarsha Raebel; Fiscal Year: 2008..The findings will also assist in developing a framework for future studies to evaluate the effects and costs of medication-laboratory monitoring among patients with diabetes. [unreadable] [unreadable] [unreadable] [unreadable]..
- PREVENTION OF STROKE DYSFUNCTION BY ACE INHIBITIONCHARLES STIER; Fiscal Year: 2003..abstract_text> ..
- PAI-1 and The Vascular Toxicity of AldosteroneNancy Brown; Fiscal Year: 2005..This multi-disciplinary approach will generate new information regarding the role of aldosterone in vascular toxicity and, thus, improve our ability to prevent and treat cardiovascular disease. ..
- Vanderbilt Mentored Clinical Research Scholar ProgramNancy Brown; Fiscal Year: 2006..The VCRS program will train successful new clinical investigators who will serve as leaders role in the post-genomic era. [unreadable] [unreadable] [unreadable]..
- RAAS, Inflammation & Post-Operative Atrial FibrillationNancy Brown; Fiscal Year: 2009..abstract_text> ..
- Lipoproteins, HIV, and Antiretroviral Therapy in SMARTDaniel Duprez; Fiscal Year: 2008..This proposal will produce additional information that will enhance their disease-free survival rate. (End of Abstract) [unreadable] [unreadable] [unreadable]..
- TRAINING CURRICULUM IN PATIENT ORIENTED RESEARCHRobert Toto; Fiscal Year: 2004..The proposed program will provide young physicians and scientists with the skills needed to conduct clinical investigations and to compete for federal and non-federal research funding. ..
- DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORSDavid Archer; Fiscal Year: 2006..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
- ACTION - A CHF Trial Investigating Outcomes of ExerciseCHRISTOPHER O CONNOR; Fiscal Year: 2008..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
- Improving Outcomes in Diabetic NephropathyRobert Toto; Fiscal Year: 2008..PERFORMANCE SITE ========================================Section End=========================================== ..
- African American Study of Kidney Disease and Hypertensi*Robert Toto; Fiscal Year: 2007..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
- Pregnane X Receptor: Regulation and PharmacogenomicsErin Schuetz; Fiscal Year: 2007..In total this proposal describes a comprehensive set of experiments to determine how PXR is regulated. ..
- International Network and Registry for TMAHoward Trachtman; Fiscal Year: 2007..These include essential hypertension, diabetes, hyperlipidemia, myocardial infarction, and chronic kidney disease. [unreadable] [unreadable]..
- Selective Modulation of Thyroid Receptor ActionJohn Baxter; Fiscal Year: 2007..This study will expand our understanding of selective TR modulation in specific and NR action in general. ..
- Michigan Mentored Clinical Scholars ProgramDavid Schteingart; Fiscal Year: 2007..On the basis of these resources, we are confident we can offer an outstanding pro_am for the training of clinical research scholars. ..
- Urinary Biomarkers for Acute Kidney Injury in Critical IllnessSteven Coca; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Aldosterone, Histone Demethylase and Cardiovascular DiseaseGordon H Williams; Fiscal Year: 2010..This project is designed to assess one of those mechanisms thereby providing entrie to developing more directed therapy to treat cardiovascular diseases. ..
- Non-Modulation Phenotype and Vascular Dysfunction in Diabetes MellitusGordon H Williams; Fiscal Year: 2010....
- Low-Renin Hypertension in African AmericansJohn Pratt; Fiscal Year: 2003..In summary, we explore unique but simple approaches to treatment of low-renin hypertension in blacks, a treatment modality that could prove useful to many patients currently with uncontrolled blood pressure. ..
- Partnership Program to Reduce Cardiovascular DisparitiesElijah Saunders; Fiscal Year: 2008..We strongly expect improved outcomes/awareness of cardiovascular health among minority patients serviced by both BSBHS and UMB. ..
- Biobehavioral Cardiovascular Health Promotion Intervention in a State Prison SystDebra K Moser; Fiscal Year: 2010..Effective management of cardiovascular risk factors could improve the health of inmates both while incarcerated and once released, and reduce the substantial personal and societal burden of cardiovascular disease. ..
- Heart Failure: Epidemiology & Outcomes in the ElderlyLesley Curtis; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Cardiovascular and renal hemodynamics and the DASH dietPaul Conlin; Fiscal Year: 2009..abstract_text> ..
- Inflammation & Prognosis in Decompensated Heart FailureGARY FELKER; Fiscal Year: 2008..Felker's development into an established independent clinical investigator with expertise in both complex clinical research methodology and the role of inflammation in the pathophysiology of heart failure. ..
- Transforming PCI Informed Consent into an Evidence-based Decision-making ToolJohn A Spertus; Fiscal Year: 2010..We will then estimate the cost-savings associated with more rational BAT use to test the hypothesis that PRISM will improve the cost-effectiveness of PCI. ..
- Drew AASK Cohort StudyKeith Norris; Fiscal Year: 2007..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
- SCHOLARS IN CLINICAL SCIENCE PROGRAMGordon Williams; Fiscal Year: 2004..abstract_text> ..
- Oral Peptide Conjugate to Treat Congestive Heart FailureKenneth James; Fiscal Year: 2003..Phase II studies will involve pharmacokinetic and pharmacodynamic studies of the most promising candidates arising from Phase I studies. ..
- Role of IGF-1 In Diastolic Dysfunction of AgingLeanne Groban; Fiscal Year: 2003..This study will provide the groundwork for future studies examining how IGF-1 signaling may modulate the programming and gene expression of the senescent myocardium. ..
- BRAIN AND CARDIAC ANGIOTENSIN II IN HYPERTENSIONKATHLEEN BERECEK; Fiscal Year: 2003..These studies are highly novel and could help to define new strategies not only for the treamtent of hypertension but its prevention as well. ..
- DST and Suicide PredictionElizabeth Young; Fiscal Year: 2003....
- Human monoclonal antibody therapy for HUSHoward Trachtman; Fiscal Year: 2004..abstract_text> ..
- Digoxin Chiral Isolates as Improved PharmaceuticalsJohn Somberg; Fiscal Year: 2005..The advantage would be a treatment for AF that did not cause cardiac augmentation and vasoconstriction or a treatment for CHF that does not cause heart rate slowing or conduction disturbances. ..
- VASCULAR DISEASE IN HBP--ANGII, PAI1, INSULIN AND GENESGordon Williams; Fiscal Year: 2001..With this information, specific preventive and therapeutic measures to retard the development of these complications could be proposed and tested in a clinical trial's format. ..
- HPA Axis in Depression and AnxietyElizabeth Young; Fiscal Year: 2005....
- Novel Therapies for Resistant FSGSHoward Trachtman; Fiscal Year: 2006..The infrastructure that is established for the performance of this R21/R33 project should prove useful for the efficient assessment of additional novel therapies that will be developed in the future for patients with primary FSGS. ..
- ANGIOTENSIN, LEPTIN, AND THE SYMPATHETIC NERVOUS SYSTEMLisa Cassis; Fiscal Year: 2001....
- Mechanisms of Aldosterone Induced Cardiovascular DamageGordon Williams; Fiscal Year: 2006..Our results should better define the rationale for the use of mineralocorticoid receptor antagonists to prevent damage to the heart and other tissues when ALDO levels are inappropriate relative to Na intake. ..
- BIOLOGY OF COMORBID DEPRESSION AND ANXIETYElizabeth Young; Fiscal Year: 2001..The results of these studies will provide data on whether the biology of these disorders support the nosological distinction between panic disorder, pure major depression and major depression with co-morbid panic disorder. ..
- VOLTAGE GATED CARDIAC POTASSIUM CHANNELSKatherine Murray; Fiscal Year: 2001....
- Neurohormonal Blockade and Outcomes in Diastolic Heart FailureAli Ahmed; Fiscal Year: 2010..angiotensin-converting enzyme inhibitors (or angiotensin receptor blockers), beta-blockers and aldosterone antagonists, in three propensity-matched populations of Organized Program to Initiate Life-Saving Treatment in ..
- Fusion Proteins As Probes of P450 Structure and FunctionRichard Auchus; Fiscal Year: 2004..In addition, this approach might be generally applicable to structural studies of membrane-bound proteins. ..
- Molecular Modulation of Cardiac Na+ Channel FunctionKatherine Murray; Fiscal Year: 2004..abstract_text> ..
- Oxidized Linoleic Acid, Aldosterone, and ObesityTHEODORE GOODFRIEND; Fiscal Year: 2007..abstract_text> ..
- Aldosterone in angiotensin II-induced hypertensionRudy Ortiz; Fiscal Year: 2005..Unlike previous studies, the present study will provide a more comprehensive examination of the renal effects induced by aldo antagonism. ..
- MICROVASC OBSTRUCTION BY MRI AFTER CORONARY INTERVENTIONKatherine Wu; Fiscal Year: 2004..abstract_text> ..
- G6PD AND OXIDANT STRESS IN VASCULAR SMOOTH MUSCLE CELLSJane Leopold; Fiscal Year: 2004..abstract_text> ..
- Beta Cell Adaptation to Stress in Baboon Pancreas After Partial PancreatectomyFRANCO BATTISTA FOLLI; Fiscal Year: 2010....
- ATHEROGENESIS AND THE BONE MARROW ANGIOTENSIN SYSTEMCarlos Ferrario; Fiscal Year: 2004..The proposed research will uncover novel mechanisms of atherogenesis that may have significant impact in the development of new therapeutic modalities applicable to cardiovascular and blood vessel diseases. ..
- Heart Failure and Beta-Blocker Use in Older AdultsAli Ahmed; Fiscal Year: 2006..abstract_text> ..
- The Effect of Aldosterone on Cerebral Blood VesselsAnne Dorrance; Fiscal Year: 2007..unreadable] [unreadable]..
- Heart failure, chronic kidney disease, and renin-angiotensin system inhibitionAli Ahmed; Fiscal Year: 2009....
- PHYSIOLOGY OF ESTROGEN'S MOOD EFFECT IN MENOPAUSAL WOMENHadine Joffe; Fiscal Year: 2007..Such training will lay the foundation for a career of clinical investigation into the physiology of perimenopausal depression and the impact of hot flushes on sleep, mood, and quality-of-life. ..
- COLLABORATIVE R01-CARDIAC GRAFTS-FUNCTIONAL ANALYSESRobert Kloner; Fiscal Year: 2003....
- Biologic Ventricular Assist DeviceRobert Kloner; Fiscal Year: 2004..Identification and characterization of transplants will be carried out with PCR analysis of the Y chromosome (male cells into female host), detailed histologic analysis and immunostaining for muscle cell markers. ..
- Mesenchymal Stem Cells for Myocardial InfarctionRobert Kloner; Fiscal Year: 2006..abstract_text> ..